Founded in 2016, Qualipat operates in Timisoara and Oradea and offers services nationwide. The company has a team of 21 employees and recorded revenue of approximately 1.2 million euros in 2025, with a monthly average of about 3,000 patients.
„Integrating Qualipat’s expertise complements the investments we have made in recent years in genetics, genomics, and molecular biology. In oncology, value is created when information obtained from pathological anatomy, immunohistochemistry, molecular biology, and genetics is interpreted together. Through this partnership, we are strengthening our ability to build diagnostic services in Romania that meet standards comparable to those of major international centers and to support the development of personalized medicine,” said Robert Beke, Executive Director of the MedLife Group Laboratory Network.
Following the transaction, the company will continue to operate under the same brand, and Prof. Dr. Ovidiu Pop will remain in his position as General Manager.
One of the main areas of development for the new partnership is accelerating the transition to digital pathology and integrating advanced artificial intelligence solutions into diagnostic processes. Joint plans include the use of FDA-validated software platforms for the interpretation and standardization of oncological biomarkers—technologies that can help increase diagnostic reproducibility and facilitate collaboration among specialists, regardless of their location.
„Joining the MedLife Group represents an opportunity to accelerate the projects developed in recent years and to expand access to infrastructure, technology, and multidisciplinary expertise. We aim to further advance modern pathology, digital pathology, and molecular diagnostics, while building centers of excellence based on physician subspecialization. We believe this integration will bring direct benefits to both the medical community and patients through faster, more standardized, and more accurate diagnostic services”, said Prof. Dr. Ovidiu Pop, CEO of Qualipat.
MedLife reported RON853 million consolidated turnover in the first quarter of 2026, 9.7% higher than in the year-earlier period, while net profit declined by 18% to RON8.8 million.
The company’s shares have gained 15% in the past year, amid RON6.3 billion capitalization.
(English version by Catalina Apostoiu)